Journal
PRIMARY CARE DIABETES
Volume 8, Issue 4, Pages 308-314Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.pcd.2014.02.004
Keywords
Diabetes mellitus type 2; Dietary protein; Low GI diet; Metabolic control; Omega-3 polyunsaturated fatty acids; Inflammation
Categories
Funding
- Federal Ministry of Economy, Family and Youth
- National Foundation for Research, Technology and Development
Ask authors/readers for more resources
Aims: The current study aims to investigate practicability and effects of a combined dietary intervention with increased relative protein content supplemented with omega-3 polyunsaturated fatty acids (PUFA) on metabolic control and inflammatory parameters in a real life situation in type 2 diabetes patients. Methods: In this observational study we advised thirty mostly obese patients with type 2 diabetes to follow a protein-enriched diet with carbohydrates of low glycemic index (low GI) and moderate fat reduction supplemented with omega-3 PUPA for 24 weeks. Primary efficacy parameter was the change in HbA1c; secondary parameters included changes in systemic inflammation (measured by ultrasensitive C-reactive protein, usCRP), body weight, waist circumference, fat mass. The study is registered at clinicaltrials.gov (NCT01474603). Results: The dietary intervention significantly reduced the primary efficacy variable HbA1c from a baseline value of 63 +/- 11 mmol/mol to 59 +/- 14 mmol/mol (P = 0.033) and 56 +/- 12 mmol/mol (P = 0.001) after 12 and 24 weeks, respectively. In addition, usCRP decreased significantly at 24 weeks (P = 0.039). Waist circumference, an important indicator for cardiometabolic-risk and silent inflammation, decreased from baseline 116.0 +/- 14.1 cm to 114.9 +/- 13.5 cm (P = 0.019), 114.0 +/- 14.4cm (P = 0.001), and 112.7 +/- 13.4cm (P = 0.049), after 3, 12 and 24 weeks, respectively. Conclusion: Counseling a protein enriched and low glycemic index diet supplemented with long-chain omega-3 PUFA in a real-life clinical setting improves glycemic control and also reduces waist circumference and silent inflammation in overweight or obese patients with type 2 diabetes. (C) 2014 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available